<DOC>
	<DOCNO>NCT02898116</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm study evaluate safety preliminary efficacy target therapy NSCLC combination checkpoint inhibitor : - Ensartinib ( X-396 ) , anaplastic lymphoma kinase ( ALK ) Inhibitor - Durvalumab ( MEDI4736 ) , anti-programmed cell death ligand 1 ( PD-L1 ) antibody .</brief_summary>
	<brief_title>A Study ALK Inhibitor , Ensartinib , Anti-PD-L1 , Durvalumab , Subjects With ALK-rearranged Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic confirmation metastatic nonsmall cell lung cancer ( NSCLC ) confirm ALK rearrangement . Measurable disease accord RECIST 1.1 . Availability archival ( diagnostic ) specimens willing undergo pretreatment biopsy . Subjects treat brain metastasis must treat surgery and/or radiation therapy â‰¥ 21 day prestudy must clinically stable . Laboratory parameter vital function normal range clinically significant . Body weight &gt; 30 kilogram . Treatment investigational agent within 4 week start treatment . Prior treatment antiPD1 , PDL1 , CTLA4 , ensartinib ( X396 ) . Active , suspect prior document autoimmune disease . Subjects clinically significant cardiovascular disease . History pneumonitis interstitial lung disease , unresolved immunerelated adverse event . Major surgery within 4 week start treatment . Active infection include tuberculosis , hepatitis B C , human immunodeficiency virus . History allogenic organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALK-rearranged</keyword>
	<keyword>ALK-positive</keyword>
	<keyword>ALK Inhibitor</keyword>
	<keyword>Ensartinib</keyword>
	<keyword>X-396</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>ALK</keyword>
</DOC>